Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli nissle in the streptomycin-treated mouse intestine

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Petersen, Andreas Munk ^a,b   Schjørring, Susanne ^a   Gerstrøm, Sarah Choi ^a   Krogfelt, Karen Angeliki ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ESCHERICHIA COLI NISSLE; PROBIOTIC AGENT; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTERITIS; ERADICATION THERAPY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; INTESTINE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; TREATMENT DURATION; ANIMAL; BACTERIAL COUNT; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MOUSE; PATHOLOGY;

MUS;

ANIMALS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; FEMALE; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICE; STREPTOMYCIN;

EID: 80051509092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022823     Document Type: Article

References (29)

1. Janowitz HD, Croen EC, Sachar DB, (1998) The role of the faecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 4 (1): 29-39.
2. Madsen KL, (2001) Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 24 (5): 250-7.
3. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (6837): 599-603.
4. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF, (2003) Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 15 (6): 627-34.
5. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, et al. (2003) CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (4): 993-1000.
6. Cooke EM, Ewins SP, Hywel-Jones J, Lennard-Jones JE, (1974) Properties of strains of Escherichia coli carried in different phases of ulcerative colitis. Gut 15 (2): 143-6.
7. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, et al. (1998) Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115 (6): 1405-13.
8. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, et al. (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2): 412-21.
9. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, et al. (2001) Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 69 (9): 5529-37.
10. Sokol H, Lepage P, Seksik P, Doré J, Marteau P, (2006) Temperature gradient gel electrophoresis of Faecal 16S rRNA reveals active Escherichia coli in the Microbiota of patients with ulcerative colitis. J Clin Microbiol 44 (9): 3172-7.
11. Kotlowski R, Bernstein CN, Sepehri S, Krause DO, (2007) High prevalence of Escherichia coli belonging to the B2+D phylogentic group in inflammatory bowel disease. Gut 56: 669-75.
12. Petersen AM, Nielsen EM, Litrup E, Brynskov J, Mirsepasi H, et al. (2009) A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease. BMC Microbiol 9: 171.
13. Marks DJ, Rahman FZ, Novelli M, Yu RC, McCartney S, et al. (2006) An exuberant inflammatory response to E. coli: Implications for the pathogenesis of ulcerative colitis and pyoderma gangrenosum. Gut 55 (11): 1662-3.
14. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, et al. (2010) Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 50 (4): 473-80.
15. Rahimi R, Nikfar S, Rezaie A, Abdollahi M, (2007) A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 52 (11): 2920-5.
16. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, et al. (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11 (5): 853-8.
17. Malchow HA, (1997) Crohn's disease and Eshcerichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25 (4): 653-8.
18. Patzer SI, Baquero MR, Bravo D, Moreno F, Hantke K, (2003) The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors RepA, Cir, Fiu and IroN. Microbiology 149: 2257-70.
19. Vejborg RM, Friis C, Hancock V, Schembri MA, Klemm P, (2010) A virulent parent with probiotic progeny: comparative genomics of Escherichia coli strains CFT073, Nissle 1917 and ABU 83972. Mol Genet Genomics 283 (5): 469-84.
20. Myhal ML, Laux DC, Cohen PS, (1982) Relative colonizing abilities of human fecal and K12 strains of Escherichia coli in the large intestines of streptomycin-treated mice. Eur J Clin Microbiol 1: 186-192.
21. McKenzie GJ, Craig NL, (2006) Fast, easy and efficient: site-specific insertion of transgenes into enterobacterial chromosomes using Tn7 without need for selection of the insertion event. BMC Microbiol 6: 39.
22. Schjørring S, Struve C, Krogfelt KA, (2008) Transfer of antimicrobial resistance plasmids from Klebsiella pneumoniae to Escherichia coli in the mouse intestine. J Antimicrob Chemother 62 (5): 1086-93.
23. Kuzela L, Kascak M, Vavrecka A, (2001) Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 96: 3218-3219.
24. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT, (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 354: 635-639.
25. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, et al. (2004) Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab 11: 372-378.
26. Leatham MP, Banerjee S, Autieri SM, Mercado-Lubo R, Conway T, et al. (2009) Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect Immun 77 (7): 2876-86.
27. Fabich AJ, Jones SA, Chowdhury FZ, Cernosek A, Anderson A, et al. (2008) Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine. Infect Immun 76 (3): 1143-52.
28. Boudeau J, Glasser A-L, Julien S, Colombel JF, Darfeuille-Michaud A, (2003) Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 18: 45-56.
29. Poulsen LK, Lan F, Kristensen CS, Hobolth P, Molin S, et al. (1994) Spatial distribution of Escherichia coli in the mouse large intestine inferred from rRNA in situ hybridization. Infect Immun 62: 5191-4.